UnknownPhase 3

Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

Russia100 participantsStarted 2016-12-10

Plain-language summary

The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence. The aim of the current study is to improve the rate and the quality of hematologic response as well as to prevent delayed complications such as relapse and clonal progression by means of adding eltrombopag to standard immunosuppressive therapy

Who can participate

Age range2 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinical diagnosis of severe and very severe Aplastic anemia
✓. 2 - 18 years old
✓. Written informed consent signed by a parent or legal guardian prior to initiation of any study specific procedure.
✓. Absence of HLA-identical family member

What they're measuring

ORR (CR + PR)

Timeframe: 4 months

Trial details

NCT IDNCT03413306

SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-10-20

Contact for this trial

Olga Goronkova, MD

+7-495-287-65-70 goronkova@yandex.ru

View on ClinicalTrials.gov More Acquired Aplastic Anemia trials